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WHAT MATHEMATICS SHOULD BE USED TO TREAT
CANCER? FOCUS ON DRUG RESISTANCE
LUÍS ALMEIDA∗, REBECCA H. CHISHOLM†, JEAN CLAIRAMBAULT‡,
TOMMASO LORENZI§, ALEXANDER LORZ¶, CAMILLE POUCHOL‖AND
EMMANUEL TRÉLAT∗∗
The clinical question of drug resistance in cancer, our initial motivation to study
continuous models of adaptive cell population dynamics, leads naturally and more
generally to consider the cancer disease itself from an evolutionary biology view-
point, a consideration without which even the best targeted therapies will likely
most often eventually fail. Among the challenging questions to mathematicians
who tackle the task of understanding this disease and optimising its treatment
are the representation of phenotypic heterogeneity of cancer cell populations and
of their plasticity in response to anticancer drug insults. Such representation can
be obtained using phenotype-structured models of healthy and cancer cell popula-
tions, and optimal control methods to optimise drug effects, with the perspective
to implement them in the therapeutics of cancer, aiming at both avoiding the
emergence of drug resistance in tumours and taking into account a constraint of
limiting unwanted adverse effects to healthy tissues.
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1. Introduction to mathematical modelling in cancer
Mathematical models of cancer growth and therapy have already known nu-
merous developments and publications in the past twenty years or so. They
belong to two general classes: agent-based models, ruled by stochastic rules
of growth (for division, death, motion, interactions with the environment)
in which the individual agents are cancer cells, and continuous models that
rely on ordinary or partial differential equations, sometimes delay differ-
ential equations, whose solutions are densities of cancer cell populations.
The benefits and limitations of these two respective classes of models, with
examples, are discussed, e.g.., in [Chisholm et al. 2016a]6. As regards
anticancer treatments, the continuous version allows to take advantage of
mathematical optimisation and optimal control algorithms that have been
designed in this framework, originally in engineering settings. A short re-
view of models designed with this therapeutic control vision is presented
for instance in [Billy and Clairambault 2013]2. It is sometimes possible
to obtain a continuous model starting from an agent-based one by averag-
ing methods; alternatively, one can also develop in parallel the two types
of models applied to the same biological problem and compare the pre-
dicted behaviour of the modelled cell populations, as e.g., in [Chisholm et
al. 2015]9, or in a general setting, in [Byrne and Drasdo 2009]4.
The goal of such models of cancer growth may be to merely understand
the biological phenomenon of cancer growth, by designing accurate mod-
els that are all the more relevant to describe a biological reality as they
are identified and validated on biological measurements in vitro in culture
dishes, in vivo on laboratory animals, or from observations (e.g. radio-
logical images) on humans, to be confronted to theoretical growth curves
depending on a priori unknown parameters (the physicist’s viewpoint). But
it may also be of a different nature, to represent the effects of treatments
on tumours, with the aim to optimise them. In the latter case, these effects
may be described either by their molecular effects on known drug targets
(keeping in mind that precision targeting is often alluring, since drugs may
have unpredictable effects on non recognised targets) or by their functional
effects on the possible fates of cell populations, namely proliferation, ex-
tinction, differentiation or senescence. The respective advantages of these
two points of view are also discussed, with examples, in [Chisholm et al.
2016a]6. Whatever the chosen point of view, molecular or functional, the
goal of these models is here clearly established as understanding and im-
proving the efficacy of anticancer treatments (the physician’s viewpoint).
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2. Drug resistance in cancer
2.1. The two main pitfalls of cancer therapeutics
Unwanted toxic side effects on healthy cell populations and emergence of
resistance to treatments in cancer cell populations are the two main pitfalls
of cancer therapeutics in the clinic. Toxicity is always a concern for the
clinician, as it limits the tolerable doses of drugs delivered to the patient,
who otherwise might see his tumours eradicated, but at the expense of
deadly insults to essential organs or functions (haematopoiesis, digestion,
skin covering, liver function, heart function). It has lately been proposed
that instead of delivering for short periods of time the maximum tolerated
dose (MTD), it might be as efficient to deliver small drug doses (the so-
called metronomic strategy), thus minimising toxicity, with as good results
on the cancer cell population. To what extent is the immune system in-
volved in the efficacy of this new way of designing delivery schedules is not
completely clear and might depend on the anticancer drug in use [Zitvogel et
al. 2008, 2011]40,41, however metronomic therapies certainly challenge the
MTD strategy in both limitation of toxicity and improvement of efficacy.
Note that an initial interpretation of the success of metronomic therapies
was more mechanic, postulating that too high amounts of drugs destroy the
blood vessels that bring the drugs to the tumour [Benzekry and Hahnfeldt
2013, Pasquier et al. 2010]1,28. It is not exclusive of the immunogenic ex-
planation [Zitvogel et al. 2008, 2011]40,41, which proposes that giving small
drug doses may reveal hidden (internalised) cancer antigens by shattering
a small number of cancer cells, enough to trigger an efficient immune re-
sponse towards the whole cancer cell population. Both explanations still
remain to be more biologically documented - especially with respect to the
immune response -, mathematically modelled and tried in clinical settings;
however, they address the question of toxicity in an apparently paradoxical
way (“more is not necessarily better”) that is a challenge for modellers.
Drug resistance, the other major pitfall of cancer therapeutics, is a treat-
ment efficacy limitation of another nature; it may be defined as adaptation
of the target cancer cell populations to the hostile environment created by
the drug. Resistance to treatments in cancer cell populations, insofar as
it is not constitutive of organisms therapies apply to, but secondary, i.e.,
induced by treatments as a stress response. In many cases (in fact, in
most cases), treatments that show remarkable initial efficacy by drastically
shrinking tumours see their response decrease with time, until they become
totally inefficient as tumours regrow. Furthermore, the newly growing can-
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cer cell populations, that have become resistant to the drug in use, are out
of reach for this therapy, and often for others that have not been employed
(multi-drug resistance). At the molecular scale, different mechanisms have
been identified, such as overexpression of drug efflux pumps (ABC trans-
porters [Gottesman et al. 2002]16, such as the P-glycoprotein, also known
as MDR1, or ABCB1), of intracellular drug processing enzymes or of DNA
repair enzymes, and it has been proposed to combine cytotoxic drugs with
inhibitors of these mechanisms, unfortunately eventually to no avail. As
mentioned above, the molecular point of view in pharmacological treat-
ments in principle offers a satisfying framework to perform cancer treatment
optimisation, but so-called targeted therapies (i.e., that target intracellular
molecular pathways), with a few exceptions, result in disappointing out-
comes (see, e.g., [Gillies et al. 2012, Goldman et al. 2017a]13,14).
2.2. From the single cancer cell to cancer cell populations
Indeed, these treatments share the same flaw, which is that they focus on a
given molecular target (or on several molecular targets), considering cancer
as the disease of the same single cell extended to large quantities, instead
of taking into account the population of cancer cells in its diversity, which
might offer a key explanation of their failure [Goldman et al. 2017b]15.
Such population diversity (or heterogeneity) is not necessarily of genetic
nature but linked to epigenetic changes in the chromatin, thus reversible
[Sharma et al. 2010]35, at least on the initiation of drug resistance (mu-
tations can come later to irreversibly establish resistance in a subclone of
the cell population), and may result in differently expressed phenotypes
in different cells, potentially inducing different resistance mechanisms as
responses to cytotoxic stress in a population of cells bearing all the same
genotype.
Introducing the population of cancer cells (indeed, the actual target of
anticancer treatments) naturally sets the scenery for Darwinian evolution
of cells exposed to anticancer drugs seen as an environmental selection pres-
sure, as will be developed in the next section. This viewpoint, introduced
in theoretical ecology for quite a long time already, is rather new in bi-
ology and medicine (where it has given rise to the new field of Darwinian
medicine), however, does not allow to decide whether the selection is of pure
Darwinian nature (selection of the fittest, cells that were already present
in the population before exposure to the drug) or may involve a part of
Lamarckian adaptation (no resistant cells initially present, but stochastic
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triggering of resistance mechanisms in a few cells for which the response to
stress happens to be well adapted to resist the cytotoxic effects of the drug
in use). This alternative, discussed in a mathematical setting in [Chisholm
et al. 2015]9 was already the object of the biological experiment by Luria
and Delbrück [Luria and Delbrück 1943]27, concluding to sheer Darwinian
selection. However, Luria and Delbrück’s experiment was performed not on
cancer cells exposed to drugs, but on bacteria exposed to bacterium-eating
viruses (phages), while human and animal cancer cells bear a genome - and
epigenome, i.e., chromatin (histones) - than is by far richer than the bac-
terial genome, which in our case does not allow to conclude. Nevertheless,
the cell population point of view clearly opens new ways to understand and
overcome drug resistance in cancer.
3. Cancer as evolutionary disease
3.1. Evolution of multicellularity and cancer
Darwinian evolution (together with possible Lamarckian adaptation) of
cancer - and healthy - cell populations (but healthy cell populations are
in principle well controlled as regards their possibilities of phenotype evo-
lution) must of course be considered on the short-time level of a human life
or disease, but the much larger time of evolution in the course of billions
of years, from unicellular organisms towards the organised and coherent
forms of multicellularity represented by present animals and plants, may
also shed light on cancer as evolutionary disease. Cancer is a disease of
multicellular organisms, that may be defined as loss of coherence between
tissues due to loss of coherence control by those genes that have been es-
sential in the evolution towards multicellularity. In [Davies and Lineweaver
2011]10, it is advocated that the genes that are altered in cancer are pre-
cisely the ones that have been employed by evolution to design multicellular
organisms. Indeed, evolution proceeds, as stated by Nobel prize laureate
François Jacob in [Jacob 1977]20, by tinkering, i.e., it proceeds by trials and
errors taking advantage of any existing material, and, as regards multicel-
lularity, such tinkering may result in localised (in organs and physiologi-
cal functions elicited by corresponding genes) fragilities, that secondarily,
under environmental pressure, may be caught off guard and result in lo-
calised cancers. Such loss of coherence control, unmasking a pluripotent
phenotype that is also named plasticity, may in particular be seen in the
process of de-differentiation of cancer cells, i.e., adoption of a pluripoten-
tial phenotype (eventually yielding the so-called ‘cancer stem cell’, whose
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existence is likely to be transient [Li and Laterra 2012]23) making the cells
that bear it, as endowed with a rich panel of non-repressed genes, able to
develop a wide variety of responses to cytotoxic stress. The involvement of
such failed multicellularity (i.e., unpreserved normal differentiation) con-
trol genes in revealing an ancient ‘toolkit’ of prexisting adaptations [Davies
and Lineweaver 2011]10 still remains to be documented, but it certainly
offers new ways of considering cancer as an evolutionary disease and drug
resistance in cancer as an evolutionary - and adaptive - mechanism.
3.2. Heterogeneity and plasticity in cancer cell populations
Heterogeneity in cancer cell populations has been documented in advanced
solid tumours as of genetic nature, with evidence of multiple branched mu-
tations [Gerlinger et al. 2012]12, but, as mentioned above, it may also con-
sist of sheer epigenetic and reversible modifications [Sharma et al. 2010]35
linked to enzymatic activities located on the chromatin, i.e., without muta-
tions in the genome. However, as recently shown in [Shaffer et al. 2017]34,
such fast epigenetic, non genetic, reprogramming of a sparse subpopulation
of cancer cells may eventually result in a stably resistant state.
Another look at heterogeneity induced in cancer cell populations by
exposure to cytotoxic drugs is presented in [Wu et al. 2015]39. In this
article, it is proposed that so-called cold genes, that have been identified
as expressed in the genome of cancer cells (multiple myeloma cells) have
a very ancient origin, being conserved without changes throughout evo-
lution from unicellularity, and may be responsible for stress response in
extremely hostile and unpredictable situations (resulting from events com-
parable, mutatis mutandis, to the impact on animal life of the meteorite
that 66 million years ago hit the Earth - creating the Chicxulub crater in
Yucatán -, subsequently putting an end to the dominance of dinosaurs), by
possibly launching secondary expression of various resistance mechanisms.
In this respect, these very ancient ‘cold genes’, elaborated in a remote past
of our planet, when conditions of life were different from the present (UV
radiation, acidity, low oxygen concentration in the oceans and in the atmo-
sphere), might be the genetic toolkit of preexisting adaptations mentioned
above, or part of it.
The variety of resistance mechanisms developed by cancer cell popula-
tions exposed to letal doses of cytotoxic drugs - an extremely hostile and
unpredictable situation for any cell population - has been related to what
is called bet hedging in theoretical ecology. The term ‘bet hedging’ is used
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to qualify behaviour relying on an ensemble of traits that make a popula-
tion of living individuals adaptable to an unpredictable environment, using
a so-called ‘risk-spreading strategy’ , that at the scale of the population,
may result in keeping safe only a small part of it, but a part that will be
able to reconstitute the whole population, with preservation of its common
genome, after such adaptation to the new environment [Philippi and Seger
1989]30. Bet hedging in tumours has been proposed as a stochastic ‘cancer
strategy’ in [Brutovsky and Horvath 2013]3. It is also presented as “an ul-
timate explanation of intra-tumour heterogeneity” in chapter XVII of the
book [Ujvari, Roche and Thomas 2017]37.
Plasticity, mentioned above about de-differentiation of cancer cells and
the transient state of cancer stem cell, may be evidenced at the level of
the single cell (derepression of genes that must be epigenetically repressed
in physiology to produce the differentiation that yields about 200 differ-
ent functional cell types in the human organism), but also at the level
of the cell population, since the spreading of such pluripotent cells makes
the population adaptable to environmental changes (plastic), possibly by
using expression of cold genes in a tiny subpopulation and stochastic (or
distributed) bet hedging of resistance phenotypes.
The plasticity - physiologically normal in highly undifferentiated cell
states, close to stem cells, but totally pathological in cell populations
for which a defined terminal physiological function exists - of the epige-
netic landscape of a given human genome, as metaphorically proposed in
[Waddington 1957]38, recently revised from a systems biology viewpoint by
Sui Huang, see, e.g., [Huang 2011, 2013]17,18, provides another approach to
plasticity and evolution of cancer, that has been for instance exploited to
study lineage commitment in haematopoiesis by using bifurcation analysis
of an ordinary differential equation model [Huang et al. 2007]19.
4. Continuous mathematical models
4.1. Phenotype-structured mathematical models
The modelling framework of adaptive dynamics we present here is more
likely to correspond biologically to epigenetic modifications rather than to
genetic mutations, as the evolution in phenotype is in this mathematical
setting always reversible (not to mention that, in the case of the application
to drug resistance in cancer that we have in mind, eventual induction of
emergent resistant cell clones due to mutations under drug pressure is never
to be excluded in the long run). From the biologist’s point of view, we
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study phenotypically heterogeneous, but genetically homogeneous, cancer
cell populations under stress (in particular by cytotoxic drugs).
The models considered here are all based on the so-called logistic ODE
model, which we recall here. It is given by the equation
dN
dt
= (r − dN)N,
which describes the time-evolution of the number of cells N(t), starting
from a prescribed initial condition N0.
Coefficient r denotes the net selection rate of the cells, namely the dif-
ference between their proliferation and death rates, while the logistic term
dN stands for an additional death rate proportional to the number of cells.
The underlying assumption is that competition for nutrients and space
inside the population does not allow for exponential unconstrained prolifer-
ation. Mathematically, it is indeed true that if N0 ≤ rd , then N(t) converges
increasingly toward the carrying capacity rd .
Let us now introduce a basic phenotype-structured model, where the
quantity of interest is a number of cells n(t, x) at time t > 0, and of phe-
notype expression level (hereafter simply designed as phenotype) x ∈ [0, 1]
standing for the resistance to a given drug. We stress that this phenotype is
taken to be continuous, because, as already mentioned, it can be correlated
to biological characteristics which themselves are continuous. Here, [0, 1]
is taken for simplicity but multi-dimensional phenotypes can of course be
considered.
The model reads
∂n
∂t
(t, x) = (r(x)− d(x)ρ(t))n(t, x),
where ρ(t) :=
∫ 1
0 n(t, x) dx is the total number of cells at time t, starting
from some initial condition n0(·). As before, r(x) is the net proliferation
rate of cells of cells of phenotype x, while d(x)ρ(t) is the natural extension
of the previous logistic term. Note that more general logistic death terms
through a Kernel K can be considered, in the form
∫ 1
0 K(x, y)n(t, y) dy.
The basic model described above is characterised by two main phenom-
ena: convergence and concentration. The first one means convergence of
ρ(t) towards max
(
r
d
)
, and concentration of the density n on the set of
phenotypes where rd reaches its maximum, namely arg max
(
r
d
)
. This is
why this class of models is extensively used in adaptive dynamics to model
selection: only the cells in the fittest phenotypic states can survive, which
corresponds mathematically to the convergence of n(t, ·) to a sum of Dirac
masses located on the set arg max
(
r
d
)
.
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This modelling framework also extends to several populations, in which
case the competition between the populations is modelled through Lotka-
Volterra-like terms. Let us introduce a model of two interacting popula-
tions, which will be further developed in the next section with the modelling
of chemotherapy as control terms. It is concerned with two densities of
healthy and cancer cells nH(t, x) and nC(t, x) respectively, where x is again
a continuous phenotype, in the application we have in mind describing the
level of resistance to a given drug. The model is given by
∂nH
∂t
=
[
rH(x)− dH(x) (aHHρH(t) + aHCρC(t))
]
nH(t, x), (1)
∂nC
∂t
=
[
rC(x)− dC(x) (aCCρC(t) + aCHρH(t))
]
nC(t, x), (2)
where, as before, ρH(t) =
∫ 1
0 nH(t, x) dx, ρC(t) =
∫ 1
0 nC(t, x) dx. The lo-
gistic terms now incorporate an intraspecific competition term weighted by
coefficients aHC and aCH . Because healthy and cancer cells compete harder
within their own population than with the other population (in other words,
cells belong to different ecological niches, e.g., for metabolic and energetic
reasons linked in particular to respiratory oxidative phosphorylation in one
case and glycolysis in the other), it is quite natural to assume
aHC < aHH , aCH < aCC .
Under hypothesis (4.1), it is proved in [Pouchol et al. 2016]32 that
the behaviour of (1) is again convergence and concentration, where the
asymptotic values of ρH , ρC and the sets on which nH , nC concentrate can
also be explicitly computed.
4.2. Optimal control for anticancer therapeutics
Optimal control methods (reviewed in [Trélat 2005]36) applied to models of
cancer therapeutics using systems of ordinary differential equations [Car-
rère 2017; Łędżewicz and Schättler 2006, 2014]5,21,22 or of partial differential
equations [Pouchol et al. 2016]32 are the appropriate tool to theoretically
optimise cancer therapeutics, in particular by taking into account the in-
evitable emergence of drug resistance in cancer cell populations.
The built-in targets for theoretical therapeutic control that are present
in the phenotype-structured PDE models we advocate here are not sup-
posed to represent well-defined molecular effects of the drugs in use, but
rather functional effects, i.e., related to cell death (cytotoxic drugs), or
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to proliferation in the sense of slowing down the cell division cycle with-
out killing cells (cytostatic drugs). We propose that cell life-threatening
drugs (cytotoxics) induce by far more resistance in the highly plastic can-
cer cell populations than drugs that only limit their growth (cytostatics),
and that a rational combination of the two classes of drugs - and possibly
others, adding relevant targets to the model - may be optimised to propose
therapeutic control strategies to avoid the emergence of drug resistance in
tumours.
We address this optimal control problem in the context of two popula-
tions, healthy and cancer as in the model is given by (1), now complemented
with two types of drugs of infusion rates u1 and u2 for cytotoxic and cy-
tostatic drugs, respectively. The resistance phenotype x they are endowed
with is defined with respect to the cytotoxic drug pressure, and is taken
to range from sensitiveness (x = 0) to resistance (x = 1). The controlled
model thus reads
∂nH
∂t (t, x) =
[
rH (x)
1+αHu2(t) − dH(x)IH(t)− µC(x)u1(t)
]
nH(t, x),
∂nC
∂t (t, x) =
[
rC (x)
1+αCu2(t) − dC(x)IC(t)− µH(x)u1(t)
]
nC(t, x),
(3)
On a fixed therapeutic time-window [0, T ], the optimal control problem
is to choose the controls u1 and u2 so as to minimise the number of cancer
cells ρC(T ), while satisfying the three following constraints.
• remaining under maximum tolerated doses: 0 ≤ u1(t) ≤ umax1 ,
0 ≤ u2(t) ≤ umax2 ,
• avoiding the emergence of too big a tumour : ρH (t)ρH (t)+ρC (t) ≥ θHC ,
• limiting unwanted adverse effects to the healthy cell population:
ρH(t) ≥ θHρ0H .
This optimal control problem is motivated by the inefficacy of using
constant high doses of drugs, a strategy which on the long run violates
the last two constraints. This is indeed what is observed in the simulation
presented in Figure 1: although the tumour size first decreases, it is at the
expense of the cancer cell density concentrating on a resistant phenotype.
The treatment becomes inefficient and relapse occurs.
In [Pouchol et al. 2016]32, the previously defined optimal control prob-
lem is analysed both numerically and theoretically. As the time T increases,
it is found that the optimal control strategy becomes increasingly close to
a two-phase strategy.
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Figure 1. What should never be done in the clinic! Simulation with u1(t) = Cst = 3.5
and u2(t) = Cst = 2, in time T = 10. Here ρCS(t) =
∫ 1
0 (1 − x)nC(t, x) dx is a measure
of the number of sensitive cells in the cancer cell population. Constant high doses of
the cytotoxic drug yield concentration of cancer cells around a resistant phenotype. The
cancer cell population increases steadily while healthy cells decrease.
• The first phase is long, and only constant low doses as given, so as
to saturate the second constraint. At the end of this first phase,
the drug pressure has been low enough to ensure that the cancer
cell density has concentrated on a sensitive phenotype.
• The second phase is short and starts with maximum tolerated doses
for both drugs, leading to a quick decrease of both cell numbers be-
cause they are efficient on a sensitive cancer cell population. Once
the third constraint (on the heathy cell density) has been reached,
cytostatic drugs switch to some intermediate value (which can be
computed in feedback form) which allows for a further decrease of
the tumour size while keeping the healthy cell number at its lower
bound.
A numerical simulation of the optimal strategy is presented in Figure 2.
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Figure 2. Simulation of the optimal control problem for T = 60. Here, the phenotype
is concentrated on a sensitive value at the end of the first delivery phase, and eventually
likely more resistant - but for a very rare surving fraction - in the cancer cell population,
if one compares the curves showing ρC(t) and ρCS(t)/ρC(t) towards the end of the
treatment course. Delivered at a high dose for a brief duration only, followed by a medium
dose for the remaining time, the cytotoxic drug u1(t) impinges a drastic decrease, if not
total eradication, in the cancer cell population, while preserving healthy cell numbers
over a predefined threshold.
For a pratical implementation of the previous strategy, it is natural
to repeat it in a quasi-periodic manner. One can hope that after enough
cycles, the tumour will be eradicated, or at least made chronic. In order to
decide when to switch from the second short phase to another cycle with a
long first phase, one must identify markers for resistance. Indeed, as long
as constant low doses do not violate the second constraint on the relative
tumour size, they must be given to ensure that the (assumed to be plastic)
tumour is becoming sensitive to the treatment again. The switch to the
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second phase can be led as soon as the markers indicate that the tumour
has become sensitive enough again. Finally, if the healthy cells tissue is too
damaged (namely the third constraint saturates), one can hope to still let
the tumour decrease with a properly chosen cytotoxic drug infusion. When
this is no longer possible, one must switch back to the long first phase (no
infusion).
5. Future tracks in modelling for cancer therapeutics
5.1. Beyond present models to optimise cancer therapeutics
The models of adaptive population dynamics that we have presented here,
with their built-in targets for control, rely on a nonlocal Lotka-Volterra
vision of cell-cell population competition. This point of view could be
extended to other modes of interaction, which could be mutualistic or
predator-prey like, and to an arbitrary number of cell populations. For an
analysis of a mutualistic integro-differential 2x2 system modelling interac-
tions between breast cancer cells and their supporting stroma (adipocytes),
we refer to [Pouchol 2015]31, whereas a more general Lotka-Volterra-like
model for N populations is analysed in [Pouchol and Trélat, submitted]33.
The inferred asymptotic behaviour is again convergence and concentration.
Let us now come to extensions of the integro-differential setting by con-
sidering the basis 1-dimensional model that we first mentioned. Recall first
that more general logistic interaction terms can be considered. The other
natural extension is to model epimutations (occurring on the relevant time-
scale, which is here that of a tumour). They can either be modelled by a
Laplacian, leading to
∂n
∂t
(t, x) = (r(x)− d(x)ρ(t))n(t, x) + β∆n(t, x),
with Neumann boundary conditions, or more generally through a mutation
kernel. Note that both modelling are linked at the limit through a proper
rescaling of the kernel, as explained in [Perthame 2007]29.
A complementary advection term can be added, accounting for cells
actively adapting to their environment, seeking for phenotype changes that
make them fitter. These can be seen as stress-induced epimutations and
with them the model becomes
∂n
∂t
(t, x) + ∂
∂x
(v(x)n(t, x)) = (r(x)− d(x)ρ(t))n(t, x) + β∆n(t, x).
Note that in [Chisholm et al. 2015]9, the advection happens to be compul-
sory to observe quick enough dynamics to fit those obtained in the exper-
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iments presented in [Sharma et al. 2010]35. Besides, in [Chisholm et al.
2016b]7, the effects of an additional advection term are rigorously studied.
A further advantage of these more general PDE models is that they are
able to represent possible asymptotic coexistence of phenotypes, which is
not the typical output of the integro-differential models. Moreover, whereas
in [Chisholm et al. 2015]9 the agent-based model and the PDE model
were treated concurrently in parallel, in Chisholm et al. 2016c]8, a general
method describing the passage from the former to the latter is rigorously
presented.
A final possible extension worth-mentioning is the addition of a space
variable, since it is believed that the heterogeneity of a tumour varies from
its periphery to its center. This is also particularly relevant in view of
optimal control through chemotherapy since drugs will efficientlly access
the outer rim of the tumour but less its core. For possible cancer models
taking both phenotype and space into account, we refer to [Lorz et al.
2015]26.
5.2. Need for models with a larger evolutionary perspective
From the biological part of this article, it clearly appears that the above-
mentioned models, sophisticated though they may be, are not enough to
study in mathematical settings the evolution of multicellularity and its
intrinsic failure, namely cancer, nor are they presently enough to design
optimised therapeutic strategies that can overcome drug resistance in can-
cer. Open questions to biologists remain if one wants to make available a
framework within which mathematical modelling may be designed. What
are the genes that must be silenced in physiology and are re-expressed in
de-differentiated cancer cells? What are the observable links between genes
that are known to be essential for multicellularity and what are the genes
that are altered in cancer (the same, following [Davies and Lineweaver
2011]10])? What models to study physiological coherence between tissues
in the same organism, i.e., what sticks together in harmony the 200 dif-
ferent cell types of a human organism? What part of the genome bears
the so-called cold genes, what part the individual signature of an organism
that is transmitted throughout differentiation (the ‘self’, certainly to be
related with the major histocompatibility complex, MHC), and what part
the genes that are normally sequentially silenced in the history of differen-
tiations? As regards mechanisms of drug resistance, what part of launching
in a cancer cell population is deterministic (triggering cold genes) and what
September 26, 2017 17:32 Proceedings Trim Size: 9in x 6in ClairambaultMoscowBiomatProc2017
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part is stochastic? And such list of open questions is not intended to be
comprehensive.
6. Conclusion: a challenging new field for mathematicians
In this short description of cancer as evolutionary disease, focusing on the
question of drug resistance and its possible overcoming by optimised strate-
gies in the clinic, we have presented what has been recently developed in
the framework of mathematical modelling, that is, adaptive dynamics of cell
populations represented by phenotype-structured models relying on partial
differential equations, together with optimal control methods to guide their
asymptotic behaviour. We have also proposed immediate tracks for future
extensions of these existing models, and only sketched the scenery for future
mathematical models that still lack biological answers to guide their design.
We are nevertheless confident in the fast progress of cancer biology to help
mathematicians design models that can be helpful in prevention, predic-
tion and control of cancer in the clinic, provided that the right questions
are posed, mathematically challenged and experimentally tackled.
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